CD69 and neoplasm: Interestingly, in mice treated with the combination TAB004 + Lip-MSA-IL-2 or TAB004 alone, we observed a significant decrease in the percent of tumor-associated CD45+ lymphocytes and of CD8+CD69+ T lymphocytes compared to tumors from mice treated with PBS or Lip-MSA-IL-2 alone (P < 0.01; Figures 3C,D).